



coordinated care™

Abecma (Idecabtagene Vicleucel Suspension for IV Infusion)

WA.PHAR.111 Abecma (Idecabtagene Vicleucel Suspension for IV Infusion)

Effective Date: 01/01/2021

Background:

ABECMA is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody (1).

All requests for authorization or payment must be referred to the Health Care Authority.

Coding:

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Code	Description
Unlisted	

*National Drug Codes:

National Drug Code	Description
59572-0515-01 59572-0515-02 59572-0515-03	ABECMA (IDECABTAGENE VICLEUCEL SUSPENSION FOR IV INFUSION)

*Please note that the NDCs listed may not be an all-inclusive list

History

Date	Action and Summary of Changes
04/12/2021	<ul style="list-style-type: none"> New Policy Created

Policy: Abecma (Idecabtagene Vicleucel Suspension for IV Infusion)
Last Updated: 04/12/2021